Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany.
Department of Radiology, Ruhr-University Bochum, Bochum, Germany.
Immunotherapy. 2021 Aug;13(11):885-891. doi: 10.2217/imt-2021-0022. Epub 2021 Jul 7.
To find out whether treatment with immune checkpoint inhibitors (ICIs) results in volume increase of the spleen. We studied 49 stage III and IV melanoma patients with an indication for ICIs. Computer tomographic-assisted volumetry of spleens was performed. After 3 months, median spleen volume was significantly increased when compared with the baseline volume. At 3 months, the increase of spleen volume was significantly associated with the use of ipilimumab and ipilimumab plus nivolumab. There was no significant association between spleen volume increase and clinical parameters. The median spleen volume of patients with cutaneous melanoma increases during the first months of ICI treatment, which was particularly attributable to the use of anti-CTLA-4 and anti-CTLA-4/anti-PD-1 regimens.
为了确定免疫检查点抑制剂（ICI）治疗是否会导致脾脏体积增加，我们研究了 49 名有 ICI 治疗指征的 III 期和 IV 期黑色素瘤患者。采用计算机断层扫描辅助脾脏体积测量。与基线体积相比，3 个月后脾脏体积中位数明显增加。在 3 个月时，脾脏体积的增加与使用伊匹单抗和伊匹单抗联合纳武单抗显著相关。脾脏体积增加与临床参数之间无显著相关性。在 ICI 治疗的最初几个月，皮肤黑色素瘤患者的脾脏体积中位数增加，这主要归因于抗 CTLA-4 和抗 CTLA-4/抗 PD-1 方案的使用。
